108 related articles for article (PubMed ID: 16277667)
1. Molecular and cytological features of the mouse B-cell lymphoma line iMycEmu-1.
Han SS; Shaffer AL; Peng L; Chung ST; Lim JH; Maeng S; Kim JS; McNeil N; Ried T; Staudt LM; Janz S
Mol Cancer; 2005 Nov; 4():40. PubMed ID: 16277667
[TBL] [Abstract][Full Text] [Related]
2. CDDO-Imidazolide inhibits growth and survival of c-Myc-induced mouse B cell and plasma cell neoplasms.
Han SS; Peng L; Chung ST; DuBois W; Maeng SH; Shaffer AL; Sporn MB; Janz S
Mol Cancer; 2006 Jun; 5():22. PubMed ID: 16759389
[TBL] [Abstract][Full Text] [Related]
3. Plasma cell tumour progression in iMycEmu gene-insertion mice.
Kim JS; Han SS; Park SS; McNeil N; Janz S
J Pathol; 2006 May; 209(1):44-55. PubMed ID: 16482495
[TBL] [Abstract][Full Text] [Related]
4. A non-transgenic mouse model for B-cell lymphoma: in vivo infection of p53-null bone marrow progenitors by a Myc retrovirus is sufficient for tumorigenesis.
Yu D; Thomas-Tikhonenko A
Oncogene; 2002 Mar; 21(12):1922-7. PubMed ID: 11896625
[TBL] [Abstract][Full Text] [Related]
5. Gene expression profiling reveals different pathways related to Abl and other genes that cooperate with c-Myc in a model of plasma cell neoplasia.
Park ES; Shaughnessy JD; Gupta S; Wang H; Lee JS; Woo HG; Zhan F; Owens JD; Potter M; Janz S; Mushinski JF
BMC Genomics; 2007 Aug; 8():302. PubMed ID: 17764563
[TBL] [Abstract][Full Text] [Related]
6. Insertion of Myc into Igh accelerates peritoneal plasmacytomas in mice.
Park SS; Shaffer AL; Kim JS; duBois W; Potter M; Staudt LM; Janz S
Cancer Res; 2005 Sep; 65(17):7644-52. PubMed ID: 16140930
[TBL] [Abstract][Full Text] [Related]
7. Insertion of c-Myc into Igh induces B-cell and plasma-cell neoplasms in mice.
Park SS; Kim JS; Tessarollo L; Owens JD; Peng L; Han SS; Tae Chung S; Torrey TA; Cheung WC; Polakiewicz RD; McNeil N; Ried T; Mushinski JF; Morse HC; Janz S
Cancer Res; 2005 Feb; 65(4):1306-15. PubMed ID: 15735016
[TBL] [Abstract][Full Text] [Related]
8. Myc translocations in B cell and plasma cell neoplasms.
Janz S
DNA Repair (Amst); 2006 Sep; 5(9-10):1213-24. PubMed ID: 16815105
[TBL] [Abstract][Full Text] [Related]
9. Ink4c is dispensable for tumor suppression in Myc-induced B-cell lymphomagenesis.
Nilsson LM; Keller UB; Yang C; Nilsson JA; Cleveland JL; Roussel MF
Oncogene; 2007 May; 26(20):2833-9. PubMed ID: 17099725
[TBL] [Abstract][Full Text] [Related]
10. AKT signalling is required for ribosomal RNA synthesis and progression of Eμ-Myc B-cell lymphoma in vivo.
Devlin JR; Hannan KM; Ng PY; Bywater MJ; Shortt J; Cullinane C; McArthur GA; Johnstone RW; Hannan RD; Pearson RB
FEBS J; 2013 Nov; 280(21):5307-16. PubMed ID: 23331925
[TBL] [Abstract][Full Text] [Related]
11. AID and RAG1 do not contribute to lymphomagenesis in Emu c-myc transgenic mice.
Nepal RM; Zaheen A; Basit W; Li L; Berger SA; Martin A
Oncogene; 2008 Aug; 27(34):4752-6. PubMed ID: 18408759
[TBL] [Abstract][Full Text] [Related]
12. B-cell tumorigenesis in mice carrying a yeast artificial chromosome-based immunoglobulin heavy/c-myc translocus is independent of the heavy chain intron enhancer (Emu).
Palomo C; Zou X; Nicholson IC; Bützler C; Brüggemann M
Cancer Res; 1999 Nov; 59(21):5625-8. PubMed ID: 10554044
[TBL] [Abstract][Full Text] [Related]
13. U-2973, a novel B-cell line established from a patient with a mature B-cell leukemia displaying concurrent t(14;18) and MYC translocation to a non-IG gene partner.
Boström H; Leuchowius KJ; Hallböök H; Nordgren A; Thörn I; Thorselius M; Rosenquist R; Söderberg O; Sundström C
Eur J Haematol; 2008 Sep; 81(3):218-25. PubMed ID: 18510704
[TBL] [Abstract][Full Text] [Related]
14. Long noncoding RNAs as a novel component of the Myc transcriptional network.
Winkle M; van den Berg A; Tayari M; Sietzema J; Terpstra M; Kortman G; de Jong D; Visser L; Diepstra A; Kok K; Kluiver J
FASEB J; 2015 Jun; 29(6):2338-46. PubMed ID: 25690653
[TBL] [Abstract][Full Text] [Related]
15. Transgenic N-myc mouse model for indolent B cell lymphoma: tumor characterization and analysis of genetic alterations in spontaneous and retrovirally accelerated tumors.
Sheppard RD; Samant SA; Rosenberg M; Silver LM; Cole MD
Oncogene; 1998 Oct; 17(16):2073-85. PubMed ID: 9798678
[TBL] [Abstract][Full Text] [Related]
16. MYC selects against reduced BCL2A1/A1 protein expression during B cell lymphomagenesis.
Sochalska M; Schuler F; Weiss JG; Prchal-Murphy M; Sexl V; Villunger A
Oncogene; 2017 Apr; 36(15):2066-2073. PubMed ID: 27694901
[TBL] [Abstract][Full Text] [Related]
17. Novel targeted deregulation of c-Myc cooperates with Bcl-X(L) to cause plasma cell neoplasms in mice.
Cheung WC; Kim JS; Linden M; Peng L; Van Ness B; Polakiewicz RD; Janz S
J Clin Invest; 2004 Jun; 113(12):1763-73. PubMed ID: 15199411
[TBL] [Abstract][Full Text] [Related]
18. Microarray analysis of B-cell lymphoma cell lines with the t(14;18).
Robetorye RS; Bohling SD; Morgan JW; Fillmore GC; Lim MS; Elenitoba-Johnson KS
J Mol Diagn; 2002 Aug; 4(3):123-36. PubMed ID: 12169673
[TBL] [Abstract][Full Text] [Related]
19. FoxO3 suppresses Myc-driven lymphomagenesis.
Vandenberg CJ; Motoyama N; Cory S
Cell Death Dis; 2016 Jan; 6(1):e2046. PubMed ID: 26764572
[TBL] [Abstract][Full Text] [Related]
20. Functional validation of genes implicated in lymphomagenesis: an in vivo selection assay using a Myc-induced B-cell tumor.
Yu D; Cozma D; Park A; Thomas-Tikhonenko A
Ann N Y Acad Sci; 2005 Nov; 1059():145-59. PubMed ID: 16382050
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
